NCT01825447View on ClinicalTrials.gov

A Study to Characterize the Abuse Liability of Intravenous Oxycodone Alone or in Combination With Intravenous Naltrexone in Healthy, Non-Dependent, Recreational Opioid Users

PHASE1CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Healthy
Interventions
DRUG

Placebo

0.9% sodium chloride for injection x 1 dose administered intravenously (IV) push over 4 min.

DRUG

Oxycodone + Naltrexone

Oxycodone hydrochloride (HCl) 20 mg IV and naltrexone HCl 2.4 mg IV administered simultaneously x 1 dose IV push over 4 min.

DRUG

Oxycodone

Oxycodone HCl 20 mg for injection x 1 dose IV push over 4 min.

Trial Locations (1)

84106

Pfizer Investigational Site, Salt Lake City

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
collaborator

Lifetree Clinical Research Center, Salt Lake City, Utah

UNKNOWN

lead

Pfizer

INDUSTRY

NCT01825447 - A Study to Characterize the Abuse Liability of Intravenous Oxycodone Alone or in Combination With Intravenous Naltrexone in Healthy, Non-Dependent, Recreational Opioid Users | Biotech Hunter | Biotech Hunter